• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Cell >Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: Implications for scheduling of anti-angiogenic drugs
【24h】

Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: Implications for scheduling of anti-angiogenic drugs

机译：vegf治疗后肿瘤向肿瘤的化学传递迅速减少：计划抗血管生成药物的意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([ 11C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [ 11C]docetaxel within 5hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.
机译：将抗血管生成药物与化学疗法相结合的当前策略可为癌症患者提供临床益处。假定抗血管生成药物（例如贝伐单抗）可暂时使异常的肿瘤血管系统正常化，并有助于改善后续化疗的递送。为了研究这一概念，使用正电子发射断层扫描（PET）和放射性标记的多西他赛（[11C]多西他赛）对非小细胞肺癌（NSCLC）患者进行了研究。在NSCLC中，贝伐单抗在5小时内降低了[11C]多西他赛的灌注和净流入率。这些效果在4天后仍然存在。这些发现的临床意义是值得注意的，因为没有证据表明药物对肿瘤的递送有实质性的改善。这些发现突出了药物调度的重要性，并提倡进一步研究以优化抗血管生成药物的调度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号